These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

846 related articles for article (PubMed ID: 25523746)

  • 1. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
    Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
    MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells.
    Reusch U; Duell J; Ellwanger K; Herbrecht C; Knackmuss SH; Fucek I; Eser M; McAleese F; Molkenthin V; Gall FL; Topp M; Little M; Zhukovsky EA
    MAbs; 2015; 7(3):584-604. PubMed ID: 25875246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis.
    Xie Z; Guo N; Yu M; Hu M; Shen B
    J Immunol Methods; 2005 Jan; 296(1-2):95-101. PubMed ID: 15680154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabody-based recombinant formats of humanized IgG-like bispecific antibody with effective retargeting of lymphocytes to tumor cells.
    Asano R; Kawaguchi H; Watanabe Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    J Immunother; 2008 Oct; 31(8):752-61. PubMed ID: 18779744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-arm binding efficiency of an EGFR x c-Met bispecific antibody.
    Zheng S; Moores S; Jarantow S; Pardinas J; Chiu M; Zhou H; Wang W
    MAbs; 2016; 8(3):551-61. PubMed ID: 26761634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humanization of the bispecific epidermal growth factor receptor x CD3 diabody and its efficacy as a potential clinical reagent.
    Asano R; Sone Y; Makabe K; Tsumoto K; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    Clin Cancer Res; 2006 Jul; 12(13):4036-42. PubMed ID: 16818703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y; Asano R; Arai K; Shimomura I; Ogata H; Kawaguchi H; Hayashi H; Ohtsuka H; Yoshida H; Katayose Y; Egawa S; Nakanishi T; Umetsu M; Yasui H; Ishida T; Imai K; Kudo T; Unno M; Kumagai I
    Oncol Rep; 2011 Oct; 26(4):949-55. PubMed ID: 21743971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity.
    Dong J; Sereno A; Aivazian D; Langley E; Miller BR; Snyder WB; Chan E; Cantele M; Morena R; Joseph IB; Boccia A; Virata C; Gamez J; Yco G; Favis M; Wu X; Graff CP; Wang Q; Rohde E; Rennard R; Berquist L; Huang F; Zhang Y; Gao SX; Ho SN; Demarest SJ; Reff ME; Hariharan K; Glaser SM
    MAbs; 2011; 3(3):273-88. PubMed ID: 21393993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
    Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
    J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
    Sheng W; Shang Y; Li L; Zhen Y
    Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
    Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
    Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
    Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
    MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Full-length recombinant antibodies from
    Rashid MH
    MAbs; 2022; 14(1):2111748. PubMed ID: 36018829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Instability of Antibody-Nanomaterial Conjugates: Next Generation Targeted Nanomedicines Using Bispecific Antibodies.
    Howard CB; Fletcher N; Houston ZH; Fuchs AV; Boase NR; Simpson JD; Raftery LJ; Ruder T; Jones ML; de Bakker CJ; Mahler SM; Thurecht KJ
    Adv Healthc Mater; 2016 Aug; 5(16):2055-68. PubMed ID: 27283923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma.
    Sagnella SM; Trieu J; Brahmbhatt H; MacDiarmid JA; MacMillan A; Whan RM; Fife CM; McCarroll JA; Gifford AJ; Ziegler DS; Kavallaris M
    Mol Cancer Ther; 2018 May; 17(5):1012-1023. PubMed ID: 29491149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.